Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Concord Biotech is an Ahmedabad-based biopharma company specialising in fermentation-derived APIs, with global leadership in immunosuppressants such as tacrolimus, mycophenolate and cyclosporine, plus oncology and anti-infective APIs. It is forward-integrating into formulations for these niches. Its moat lies in complex fermentation manufacturing capacity and regulatory approvals across the US and other regulated markets; it listed in 2023 and counts the late Rakesh Jhunjhunwala's Rare Enterprises among its backers.
It is one of the world's leading suppliers of fermentation-based immunosuppressant APIs by volume.
Concord Biotech Ltd. is a constituent of NIFTY 500, NIFTY SMALLCAP 250. See where it sits on the market heatmap →
Consolidated annual figures taken from Concord Biotech Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 24.78 | 35.52 | 29.45 |
| Book value / share (₹) | 192.62 | 173.27 | 145.93 |
| Return on equity | 12.9% | 20.5% | 20.2% |
| Return on capital employed | 14.2% | 24.4% | 24.3% |
| Operating margin | 27.8% | 37.7% | 37.2% |
| Net margin | 24.6% | 31.0% | 30.3% |
| EBITDA | ₹367 Cr | ₹506 Cr | ₹432 Cr |
| Free cash flow | ₹172 Cr | ₹133 Cr | ₹180 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹6 Cr |
| Debt to equity | 0.00 | 0.00 | 0.00 |
| Interest coverage | 1034.4 | 853.9 | 148.1 |
| Current ratio | 7.39 | 6.17 | 6.30 |
| Shares outstanding | 10,46,16,000 | 10,46,16,000 | 10,46,16,000 |
Open the full income statement, balance sheet and cash flow for CONCORDBIO →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.